Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, April 2000, p. 929-937, Vol. 44, No. 4
Department of Virology, BioChem Pharma Inc.,
Laval, Quebec, Canada H7V 4A71; Institut
für Klinische und Molekulare Virologie, 91054 Erlangen,
Germany2; MRC Collaborative Center, Mill
Hill, London, United Kingdom3;
Department of Biologic and Materials Sciences, School of
Dentistry, University of Michigan, Ann Arbor, Michigan
48109-10784; Institute for Antiviral
Research, Utah State University, Logan, Utah
843225; and Gilead Sciences, Foster
City, California 944046
Received 14 July 1999/Returned for modification 3 November
1999/Accepted 18 January 2000
A series of 1,6-naphthyridine (L. Chan, H. Jin, T. Stefanac,
J. F. Lavallee, G. Falardeau, W. Wang, J. Bedard, S. May, and L. Yuen, J. Med. Chem. 42:3023-3025, 1999) and isoquinoline (L. Chan, H. Jin, T. Stefanac, W. Wang, J. F. Lavallee, J. Bedard, and
S. May, Bioorg. Med. Chem. Lett. 9:2583-2586, 1999) analogues exhibiting a high level of anti-human cytomegalovirus (HCMV) activity were investigated in a series of studies aimed at better understanding the mechanism of action of some representatives of this class of
compounds. In vitro antiviral profiling revealed that these compounds
were active against a narrow spectrum of viruses, essentially the human
herpesviruses and type 2 rhinovirus. In HCMV assays, a 39- to 223-fold
lower 50% inhibitory concentration was obtained for compound A1 than
for ganciclovir against strains AD 169 and Towne. In addition,
ganciclovir, foscarnet, cidofovir, and BDCRB (2-bromo-5,6-dichloro-1-
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Antiviral Properties of a Series of
1,6-Naphthyridine and 7,8-Dihydroisoquinoline Derivatives
Exhibiting Potent Activity against Human Cytomegalovirus
-D-ribofuranosylbenzimidazole)-resistant HCMV strains remained susceptible to 1,6-naphthyridines and
7,8-dihydroisoquinolines tested in this study, supporting the view that
a novel mechanism of action could be involved. Drug combination studies
showed a small but significant synergistic antiviral effect between
compound B2 and ganciclovir. Cytotoxicity profiling of representative
compounds under various cell growth conditions indicated a generally
similar cytotoxic effect, relative to ganciclovir, in log-phase growing cells. However, in stationary cells, a relatively higher level of
toxicity was observed than that for control compound. Effect of time of
drug addition showed that the anti-HCMV activity of compound A1,
ganciclovir, and cidofovir was lost at approximately the same time (72 h postinfection), indicating that the compound was affecting events at
the early and late stage of virus replication. This interpretation is
also supported by reduction of de novo synthesis of pp65 tegument
protein and lack of any effect of the compound on viral adsorption. A
reduction of the HCMV enhancer-promoter-directed luciferase expression
was also observed in a stably transfected cell line when compound A1
was present at relatively high concentrations.
*
Corresponding author. Mailing address: BioChem
Pharma Inc., 275 Boul. Armand-Frappier, Laval, Quebec, Canada H7V 4A7.
Phone: (514) 978-7864. Fax: (514) 978-7946. E-mail:
bedardj{at}biochempharma.com.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»